U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838155) titled 'A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease' on Sept. 18.
Brief Summary: The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD). For each participant, the study will last up to approximately 84 weeks and will include visits every 4 weeks.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
DRUG: Donanemab
Donanemab administered IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Publish...